Soluble antigen arrays for autoimmune diseases
Orion BioScience is a preclinical stage biotechnology company focused on developing innovative therapies to intercept disease and prevent development of symptoms in autoimmune conditions such as type-1 diabetes and neuromyelitis optica.
Autoimmune diseases are unique in that the disease can go undetected for years and with currently available drug therapies doctors must wait until a formal diagnosis can be made before they can treat patients. During this time patients will experience multiple ‘attacks’ which will cause irreversible damage and reduce function of the target system. The recent advancements in diagnostic have allowed for the early identification of ‘pre-disease’ or ‘at risk’ patients, however, current treatments still require patients to be diagnosed in the diseased state. Orion is focused on developing therapies for pre-disease and at-risk patients, stopping progression into disease state. This disease interception is made possible by our ‘Soluble Antigen Array’ or ‘SAgA’ technology, which was invented by co-founders, Dr. Joshua Sestak and Prof. Cory Berkland, and exclusively licensed to Orion. ‘Soluble Antigen Arrays’ are designed to specifically target immune cells responsible for disease progression in autoimmune diseases. SAgAs target the right cells, in the right place, to turn them off and stop the disease, effectively ‘curing’ the patient. While current therapies look at shutting down all the bodies defense systems, also known as total immune suppression, in order to achieve any therapeutic efficacy SAgAs have the potential to intercept disease without the need to suppress their entire immune system.
Orion is working to advance our ‘SAgA’ technology in two distinct autoimmune conditions: type-1 diabetes, a devastating condition that targets the pancreas and insulin production in both juveniles and adults, and neuromyelitis optica, a rare and neglected neurodegenerative disease that affects mostly young adult females and results in blindness, paralysis, and in severe cases, death. In aggressive autoimmune diseases such as these, early intervention is paramount in limiting long term damage and maintaining patient health and survival. SAgAs would be the FIRST therapy available to patients that could halt disease progression before they developed the full blown autoimmune disease. Our current research into treating type-1 diabetes and neuromyelitis optica, has shown that specific immune cells or autoantibodies responsible for disease are targeted by SAgAs. Additionally, when treated with SAgAs these immune cells these immune cells send signals that can reverse disease and shut off other immune cells responsible for disease progression. These results show SAgAs promote a robust and lasting reversal of the autoimmune disease, something that is not seen with any other existing therapy.
Orion: Meeting Needs
Autoimmune diseases have a market size of over $60B. Given the broad applicability of our proprietary platforms, Orion will be able to capture revenue from out-licensing and an internal product pipeline, making us an attractive partnership or acquisition target.
Through collaborations with Dr. Larry Steinman at Stanford Univeristy and Dr. Michael Levy at Johns Hopkins University, as well as additional collaborations with Columbia University, The Univeristy of Kansas, and the Juvenile Diabetes Research Foundation, we are focused on the rapid clinical development of the SAgA platform aiming for first-in-human clinical trials in approximately 24 months. The Orion team leverages extensive development experience and strong clinical relationships to rapidly progress first-in-class treatments for patients with limited or no treatment options.
Orion: Creating Value
The combination of a ground-breaking technology, a proven and talented executive team, and collaborators and advisors ready to expedite pre-clinical and clinical efforts, uniquely positions Orion to rapidly develop novel therapies for the interception and prevention of autoimmune diseases